It would seem that BSX is oversold. But the news has been mostly bad of late. The Medinol "settlement" sounded like relief but practically the next day Medinol was back demanding more. Later it was released that the agreement covered only the past. Classic damage control. When you have really bad news release it a little at a time so the affects are spread out over time. I am becoming increasingly concerned that there are fundamental problems at BSX. There is nothing that management can be do about competition. Competition is a good thing however, it does cut into profits. But product quality and product efficacy are basic to a well run medical device company. Management has control over these elements. Management also has control to a lesser degree on agreements made with other companies. Mangement at BSX is very highly paid. You have to wonder if they are worth it.